InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
3
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the detailed record of transactions filed by Love Ted W. Director active across 5 companies, notably Seagen Inc.. In total, 28 reports have been recorded. Breakdown: 3 buys · 0 sell. History available since 14 May 2021. The latest transaction was disclosed on 5 August 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Love Ted W
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报28 总计
1,605 股0Ordinary SharesSEC:0001188919-26-000012:0
1,527 股0Ordinary SharesSEC:0001188919-26-000002:0
7,614 股0Class A Ordinary SharesSEC:0001802768-25-000055:0
1,516 股0Common StockSEC:0001127602-25-013747:0
9,293 股0Class A Ordinary SharesSEC:0001802768-24-000035:0
2,310 股0Common StockSEC:0001127602-24-014818:0
512 股0Common StockSEC:0001127602-24-003597:0
4,255 股@ US$229.00100.0% 占其流量Common StockSEC:0000950170-23-070880:0
7,747 股0Class A Ordinary SharesSEC:0001209191-23-039689:0
2,044 股0Common StockSEC:0001203311-23-000062:0
576,318 股Common StockSEC:0000899243-22-033149:0
221,200 股0Common StockSEC:0000899243-22-032261:0
9,444 股Common StockSEC:0000899243-22-030476:0
20,205 股Common StockSEC:0000899243-22-027637:0
6,328 股0Class A Ordinary SharesSEC:0000899243-22-024040:0
1,503 股0Common StockSEC:0000899243-22-018464:0
839 股@ US$25.37100.0% 占其流量Common StockSEC:0000899243-22-009236:0
29,955 股Common StockSEC:0000899243-22-004637:0
24,821 股@ US$3.4044.4% 占其流量Common StockSEC:0000899243-22-001260:0
29,955 股Common StockSEC:0000899243-21-037666:0
9,444 股Common StockSEC:0000899243-21-035219:0
29,955 股Common StockSEC:0000899243-21-031381:0
5,726 股0Class A Ordinary SharesSEC:0000950103-21-009695:0
1,402 股0Common StockSEC:0001203311-21-000033:0
1,925 股Common StockSEC:0000899243-16-012660:0
28 条申报中的 25 条
About Love Ted W
LOVE TED W is a declarant linked to Global Blood Therapeutics, Inc., Royalty Pharma plc, Seagen Inc., Gilead Sciences, INC., and Jazz Pharmaceuticals plc, with the listed role of President and CEO for Global Blood Therapeutics, Inc. and Director for the other listed companies. He has made 27 filings in total, and among the recent sampled filings there are sales of EUR 971066 between 2016-01-07 and 2026-03-02, with the transaction nature listed as Attribution.
